Zogenix Inc (USD)
ZGNX
Overview
Key Information
Legal Documents
Financials
Overview
| Sector | Healthcare |
| Industry | - |
| Day Range | 22.67 | 24.50 |
| 52-Wk Range | | |
| Last Close | 23.10 |
| Mkt Cap (m) | 1,274.57 |
| Dividend yield | - |
| ISIN | US98978L2043 |
| Volume | 735,028 |
| Exchange Venue | NAS |
Company Profile
Zogenix Inc is a pharmaceutical company engaged in commercializing and developing therapies that address clinical needs for people living with pain-related and CNS disorders that needs treatment alternatives to help return to normal daily functioning.
Key Information
| Price/Earning | - |
| Price/Book | 5.20 |
| Price/Sales | 272.78 |
| P/CF | - |
| Rev Growth (3 year avg) | -49.81 |
| EPS Growth (3 year avg) | - |
| Operating Margin % | -11628.87 |
| Net Margin % | -11499.53 |
| Return on Equity | -109.27 |
| Debt/Equity | 0.05 |
Documents
Prospectus
| en 04/03/2020 |
Annual Report
| en 31/12/2019 |
Financials
Income Statement
| USD | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Revenue (m) | 41 | 27 | 29 | 10 | - | 4 |
| Operating Income (m) | -99 | -50 | -62 | -94 | -140 | -424 |
| Net Income (m) | 9 | 26 | -70 | -127 | -124 | -420 |
| Basic EPS | 0.48 | 1.22 | -2.81 | -4.65 | -3.27 | -9.74 |
| Avg. Diluted Shares Outstanding (m) | 18 | 21 | 25 | 27 | 38 | 43 |
Balance Sheet
| USD | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Current Assets (m) | 78 | 185 | 120 | 305 | 533 | 287 |
| Non Current Assets (m) | 125 | 121 | 112 | 113 | 116 | 127 |
| Total Assets (m) | 203 | 306 | 232 | 418 | 648 | 414 |
| Current Liabilities (m) | 44 | 30 | 20 | 21 | 58 | 95 |
| Total Liabilities (m) | - | - | - | - | - | - |
| Total Equity (m) | 55 | 183 | 121 | 302 | 523 | 245 |
Cash Flows
| USD | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Operating Cash Flows (m) | -81 | -65 | -73 | -76 | -112 | -112 |
| Capital Expenditure (m) | -1 | -9 |
Figures are quoted in USD unless stated otherwise
-
No change
$
23.10
Last Price
© 2019 MeDirect Bank (Malta) plc. All rights reserved.